EGenesis Stock
EGenesis designs xenotransplantation for the benefit of human health.
Sign up today and learn more about EGenesis Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About EGenesis Stock
EGenesis designs xenotransplantation for the benefit of human health. Its technology helps transform xenotransplantation into a medical procedure, enabling clinical researchers to address the global organ shortage.
Funding History
| August 2016 | $2.0M |
|---|---|
| March 2017 | $38.0M |
| November 2019 | $100M |
Management
Chief Operating Officer
Kenneth Fan
Executive Vice President of Research and Development
William Westlin
Chief Scientific Officer
Luhan Yang
Chief Executive Officer
Paul Sekhri
Press
statnews - Apr, 7 2024
eGenesis tests gene-edited pig liver in brain-dead patient - STATbizjournals - Apr, 7 2024
Meet the Cambridge company developing gene-edited pigs for transplantation - Boston Business Journalbusinesswire - Apr, 7 2024
eGenesis Announces World's First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patientforbes - Apr, 7 2024
The Startup Behind The First Pig-Human Kidney Transplant Is Targeting Hearts And Livers Nextgenengnews - Feb, 14 2024
eGenesis, PorMedTec Engineer Pig Donors in Japan for XenotransplantationEquityZen Recognized As:
